Sodium Oxybate as a Potential New Treatment for Catatonia in Patients With Depression, Bipolar Disorder, or a Psychotic Disorder: Protocol for a Randomized Controlled Trial
JMIR Research Protocols · 2025
DOI: 10.2196/68356 ↗At a glance
Randomisierte kontrollierte Studie in JMIR Research Protocols, 2025. Written by Lilian Bot and 18 co-authors. Institution: Department of Psychiatry, Amsterdam University Medical Centers, Amsterdam, The Netherlands. Major MEDLINE topics: Catatonia, Sodium Oxybate, Psychotic Disorders, Bipolar Disorder. 29 references. The full text is freely available in PubMed Central.
Topics: Depression
Abstract (original language)
Background
Catatonia is a severe psychomotor syndrome predominantly associated with depressive, bipolar, and psychotic disorders. Untreated catatonia has a 10% mortality rate and may lead to complications such as renal failure, rhabdomyolysis, pneumonia, embolism, and contractures. High doses of the benzodiazepine lorazepam, a gamma-aminobutyric acid (GABA)-A receptor modulator, are the primary pharmacological treatment, enhancing GABA’s inhibitory effect, potentially reducing symptoms of catatonia. However, lorazepam is ineffective in about 25% of cases, leaving electroconvulsive therapy (ECT) as the only well-investigated alternative. Although often effective, ECT may have severe side effects and is not easily accepted among patients and caregivers. Therefore, there is an urgent need for novel therapies for catatonia. Sodium oxybate, a GABA precursor and GABA-B receptor agonist, is a promising alternative treatment based on observational data, but its efficacy has never been thoroughly investigated.
Objective
This study aims to evaluate the efficacy and safety of sodium oxybate in treating catatonia unresponsive to lorazepam, while also capturing the natural course and determinants of catatonia through an observational cohort.
Methods
The Laborit trial consists of a cohort study and an embedded single-blind randomized controlled trial (RCT). Patients with catatonia admitted to a psychiatric ward may join the study’s cohort, where their clinical characteristics are recorded. Standard care, including lorazepam up to 24 mg/day, will be administered. On day 4, the Bush Francis Catatonia Rating Scale (BFCRS) will be used to measure symptom response. Patients with ≤50% improvement on the BFCRS, compared to the score at start, will be eligible for the trial. A total of 42 patients will be randomly assigned to either the sodium oxybate group, after a 2-day lorazepam reduction period, or the continuation of lorazepam. The primary endpoint is response, measured by the BFCRS score change after 4 days of treatment. A ≥50% reduction in BFCRS will define a responder, who will continue allocated treatment for an additional 10 days, with a secondary endpoint at 14 days. Data will be analyzed using intention-to-treat and per-protocol methods, with chi-square and logistic regression tests to compare group response and remission rates.
Results
This study was funded by the Dutch Brain Foundation (Hersenstichting) in December 2020. The study protocol was approved by the Amsterdam UMC Ethics Board on May 22, 2023. As of March 2025, the first 4 participants have been included in the cohort, with no trial participants enrolled yet.
Conclusions
If positive, the results of this RCT may pave the way for international catatonia researchers and clinicians to introduce a new pharmacological treatment option for catatonia. Implementation could potentially benefit patients who endure this severe syndrome and present health care professionals with an additional treatment option. Trial Registration ISRCTN ISRCTN11236443; https://tinyurl.com/4px5s4aa International Registered Report Identifier (IRRID) PRR1-10.2196/68356
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Psychiatry, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
- Specialized Mental Health Care, GGZ InGeest, Amsterdam, The Netherlands.
- Amsterdam Public Health (Mental Health Program), Amsterdam University Medical Centers, Amsterdam, The Netherlands.
- Specialized Mental Health Care, Arkin, Amsterdam, The Netherlands.
- Compulsivity Impulsivity and Attention, Amsterdam Neuroscience, Amsterdam, The Netherlands.
- Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands.
ORCID profiles: Lilian Bot, Josine G van Mill, Laetitia J C A Smarius, Adriaan W Hoogendoorn, Bram W C Storosum, Christiaan H Vinkers, Gabriel E Jacobs, Gert Jan Lammers, Hanna M Heller, Jantine C A Colen-de Koning, Joris J B van der Vlugt, Marloes S Oudijn, Martijn S van Noorden, Pierre M Bet, Rolf Fronczek, Heleen S van der Heijden, Sjors M M Lange, Ysbrand D van der Werf, Eric R van Exel
Cite
APA
Bot, L., van Mill, J. G., Smarius, L. J. C. A., Hoogendoorn, A. W., Storosum, B. W. C., Vinkers, C. H., Jacobs, G. E., Lammers, G. J., Heller, H. M., Colen-de Koning, J. C. A., van der Vlugt, J. J. B., Oudijn, M. S., van Noorden, M. S., Bet, P. M., Fronczek, R., van der Heijden, H. S., Lange, S. M. M., van der Werf, Y. D., & van Exel, E. R. (2025). Sodium Oxybate as a Potential New Treatment for Catatonia in Patients With Depression, Bipolar Disorder, or a Psychotic Disorder: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. https://doi.org/10.2196/68356
Vancouver
Bot L, van Mill JG, Smarius LJCA, Hoogendoorn AW, Storosum BWC, Vinkers CH, et al. Sodium Oxybate as a Potential New Treatment for Catatonia in Patients With Depression, Bipolar Disorder, or a Psychotic Disorder: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. 2025. doi:10.2196/68356
BibTeX
@article{Bot2025,
author = {Bot, Lilian and van Mill, Josine G and Smarius, Laetitia J C A and Hoogendoorn, Adriaan W and Storosum, Bram W C and Vinkers, Christiaan H and Jacobs, Gabriel E and Lammers, Gert Jan and Heller, Hanna M and Colen-de Koning, Jantine C A and van der Vlugt, Joris J B and Oudijn, Marloes S and van Noorden, Martijn S and Bet, Pierre M and Fronczek, Rolf and van der Heijden, Heleen S and Lange, Sjors M M and van der Werf, Ysbrand D and van Exel, Eric R},
title = {Sodium Oxybate as a Potential New Treatment for Catatonia in Patients With Depression, Bipolar Disorder, or a Psychotic Disorder: Protocol for a Randomized Controlled Trial},
journal = {JMIR Research Protocols},
year = {2025},
doi = {10.2196/68356}
}
EUVIMED